Cantargia AB - Asset Resilience Ratio
Cantargia AB (CANTA) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Cantargia AB's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Cantargia AB's Asset Resilience Ratio has changed over time. See Cantargia AB (CANTA) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Cantargia AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CANTA market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Cantargia AB maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Cantargia AB Industry Peers by Asset Resilience Ratio
Compare Cantargia AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Cantargia AB (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Cantargia AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | Skr0.00 ≈ $0.00 |
Skr170.43 Million ≈ $18.34 Million |
-- |
| 2023-12-31 | 24.59% | Skr55.00 Million ≈ $5.92 Million |
Skr223.71 Million ≈ $24.07 Million |
-25.35pp |
| 2022-12-31 | 49.94% | Skr237.09 Million ≈ $25.52 Million |
Skr474.80 Million ≈ $51.10 Million |
-2.05pp |
| 2021-12-31 | 51.99% | Skr312.06 Million ≈ $33.58 Million |
Skr600.24 Million ≈ $64.60 Million |
+29.30pp |
| 2020-12-31 | 22.69% | Skr210.02 Million ≈ $22.60 Million |
Skr925.51 Million ≈ $99.60 Million |
-43.56pp |
| 2019-12-31 | 66.25% | Skr110.02 Million ≈ $11.84 Million |
Skr166.06 Million ≈ $17.87 Million |
+13.57pp |
| 2018-12-31 | 52.68% | Skr90.32 Million ≈ $9.72 Million |
Skr171.44 Million ≈ $18.45 Million |
+8.96pp |
| 2017-12-31 | 43.72% | Skr120.00 Million ≈ $12.91 Million |
Skr274.45 Million ≈ $29.54 Million |
+24.91pp |
| 2016-12-31 | 18.81% | Skr8.94 Million ≈ $961.76K |
Skr47.51 Million ≈ $5.11 Million |
-28.58pp |
| 2015-12-31 | 47.39% | Skr14.87 Million ≈ $1.60 Million |
Skr31.38 Million ≈ $3.38 Million |
-- |
About Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more